Retinoblastoma: Evolving Concepts and Future Challenges
DOI:
https://doi.org/10.12775/QS.2025.44.62962Keywords
Retinoblastoma, HeterochromiaAbstract
Retinoblastoma is the most common ocular malignancy in children. It results from mutations in the RB1 gene or from MYCN oncogene amplification. We distinguish between the more common unilateral form and the rarer bilateral form. It is important to note that bilateral retinoblastoma is always hereditary. The most common and characteristic symptom is the white pupillary reflex. In addition, the child may develop strabismus or heterochromia. Treatment methods vary, ranging from those aimed at salvaging the eye to those involving total enucleation. Prognosis depends on the location and stage of the tumor. This review aims to explore the literature on new therapeutic methods and recent discoveries in the field of retinoblastoma.
References
[1] Grossniklaus HE. Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture. Am J Ophthalmol. 2014;158(5):875-891. doi:10.1016/j.ajo.2014.07.025
[2] Cassoux N, Lumbroso L, Levy-Gabriel C, Aerts I, Doz F, Desjardins L. Retinoblastoma: Update on Current Management. Asia Pac J Ophthalmol (Phila). 2017;6(3):290-295. doi:10.22608/APO.201778
[3] Cruz-Gálvez CC, Ordaz-Favila JC, Villar-Calvo VM, Cancino-Marentes ME, Bosch-Canto V. Retinoblastoma: Review and new insights. Front Oncol. 2022;12:963780. Published 2022 Nov 2. doi:10.3389/fonc.2022.963780
[4] Nag A, Khetan V. Retinoblastoma - A comprehensive review, update and recent advances. Indian J Ophthalmol. 2024;72(6):778-788. doi:10.4103/IJO.IJO_2414_23
[5] AlAli A, Kletke S, Gallie B, Lam WC. Retinoblastoma for Pediatric Ophthalmologists. Asia Pac J Ophthalmol (Phila). 2018;7(3):160-168. doi:10.22608/APO.201870
[6] Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nat Rev Dis Primers. 2015;1:15021. Published 2015 Aug 27. doi:10.1038/nrdp.2015.21
[7] Zhou M, Tang J, Fan J, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia Pac J Ophthalmol (Phila). 2024;13(2):100058. doi:10.1016/j.apjo.2024.100058
[8] Cassoux N, Lumbroso L, Levy-Gabriel C, Aerts I, Doz F, Desjardins L. Retinoblastoma: Update on Current Management. Asia Pac J Ophthalmol (Phila). 2017;6(3):290-295. doi:10.22608/APO.201778
[9] Karcioglu ZA. Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina. 2002;22(6):707-710. doi:10.1097/00006982-200212000-00004
[10] Dimaras H, Corson TW. Retinoblastoma, the visible CNS tumor: A review. J Neurosci Res. 2019;97(1):29-44. doi:10.1002/jnr.24213
[11] Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1348-1356. doi:10.1001/archopht.1996.01100140548005
[12] Warda O, Naeem Z, Roelofs KA, Sagoo MS, Reddy MA. Retinoblastoma and vision. Eye (Lond). 2023;37(5):797-808. doi:10.1038/s41433-021-01845-y
[13] Arshad R, Barani M, Rahdar A, et al. Multi-Functionalized Nanomaterials and Nanoparticles for Diagnosis and Treatment of Retinoblastoma. Biosensors (Basel). 2021;11(4):97. Published 2021 Mar 26. doi:10.3390/bios11040097
[14] Byroju VV, Nadukkandy AS, Cordani M, Kumar LD. Retinoblastoma: present scenario and future challenges. Cell Commun Signal. 2023;21(1):226. Published 2023 Sep 4. doi:10.1186/s12964-023-01223-z
[15] Francis JH, Abramson DH, Gaillard MC, Marr BP, Beck-Popovic M, Munier FL. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015;122(6):1173-1179. doi:10.1016/j.ophtha.2015.01.017
[16] Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene. 2006;25(38):5341-5349. doi:10.1038/sj.onc.1209622
[17] Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2013;27(2):253-264. doi:10.1038/eye.2012.175
[18] Martínez-Sánchez M, Hernandez-Monge J, Rangel M, Olivares-Illana V. Retinoblastoma: from discovery to clinical management. FEBS J. 2022;289(15):4371-4382. doi:10.1111/febs.16035
[19] Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol. 2020;68(11):2356-2365. doi:10.4103/ijo.IJO_721_20
[20] Rathore S, Verma A, Ratna R, et al. Retinoblastoma: A review of the molecular basis of tumor development and its clinical correlation in shaping future targeted treatment strategies. Indian J Ophthalmol. 2023;71(7):2662-2676. doi:10.4103/IJO.IJO_3172_22
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mateusz Wiekiera, Adrianna Jasiuk, Natalia Madeja, Sylwia Koziej, Martyna Niemczuk, Emilia Kowalczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 334
Number of citations: 0
